Myeloproliferative Neoplasms

Myeloproliferative Neoplasms News & Features
The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerg

The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasm

Gender balance in cancer surveys was found to have relatively little effect on survey outcomes, according to results of a study presented at the 2022 ASCO Annual Meeting. Surveying patients with myeloproliferative neoplasms (MPN) has given valuable insight into polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) subtypes. However, independent surveys have included a…
Next post in Myeloproliferative Neoplasms